DeepMed Research

Radboud University Medical Center

🇳🇱Netherlands

Country: 🇳🇱Netherlands

Ownership: Private

Established: 1951-01-01

Employees: -

Market Cap: -

Website: http://www.radboudumc.nl

Clinical Trials

Health-related Quality of Life, Psychological Distress and Fatigue in Metastatic CRPC Patients Treated With Radium-223

Completed

Conditions: Castrate Resistant Prostate Cancer
Bone Metastases

First Posted Date: 2021-08-09

Last Posted Date: 2021-08-09

Lead Sponsor: Radboud University Medical Center

Target Recruit Count: 122

Registration Number: NCT04995614

Locations: 🇳🇱
Catharina ziekenhuis, Eindhoven, Netherlands
🇳🇱
Canisius-Wilhelmina ziekenhuis, Nijmegen, Netherlands
🇳🇱
Rijnstate ziekenhuis, Arnhem, Netherlands

and more 8 locations

Salt Supplementation in Gitelman Syndrome

Not Applicable

Completed

Conditions: Gitelman Syndrome

Interventions: Dietary Supplement: Salt (NaCl)
Other: Placebo

First Posted Date: 2021-08-09

Last Posted Date: 2024-11-21

Lead Sponsor: Radboud University Medical Center

Target Recruit Count: 21

Registration Number: NCT04995627

Locations: 🇮🇹
University Hospital of University of Campania "L. Vanvitelli", Naples, Italy
🇳🇱
Radboudumc, Nijmegen, Gelderland, Netherlands
🇳🇱
Erasmus MC, Rotterdam, Zuid-Holland, Netherlands

The Personalized Parkinson Project De Novo Cohort

Active, not recruiting

Conditions: Basal Ganglia Diseases
Parkinson Disease
Parkinsonian Disorders
Brain Diseases
Neurodegenerative Diseases
Central Nervous System Diseases
Movement Disorders
Nervous System Diseases

Interventions: Device: Verily Study Watch

First Posted Date: 2021-08-02

Last Posted Date: 2025-03-24

Lead Sponsor: Radboud University Medical Center

Target Recruit Count: 103

Registration Number: NCT04985539

Locations: 🇳🇱
Radboud University Medical Center, Nijmegen, Netherlands

Safety and Efficacy of Interferon-Gamma 1b in Patients With Candidemia

Phase 2

Recruiting

Conditions: Candidemia

Interventions: Drug: Interferon Gamma-1B

First Posted Date: 2021-07-27

Last Posted Date: 2024-12-13

Lead Sponsor: Radboud University Medical Center

Target Recruit Count: 200

Registration Number: NCT04979052

Locations: 🇺🇸
Duke University, Durham, North Carolina, United States
🇩🇪
Klinikum Der Johann Wolfgang Von Goethe Universitaet, Frankfurt am main, Germany
🇬🇷
Hellenic Institute for the Study of Sepsis (HISS), Athens, Greece

and more 3 locations

2000HIV Trained Innate Immunity in HIV Elite Controllers

Completed

Conditions: HIV-1-infection

First Posted Date: 2021-07-20

Last Posted Date: 2023-11-27

Lead Sponsor: Radboud University Medical Center

Target Recruit Count: 109

Registration Number: NCT04968717

Locations: 🇳🇱
OLVG, Amsterdam, Netherlands
🇳🇱
Erasmus MC, Rotterdam, Netherlands
🇳🇱
Radboudumc, Nijmegen, Netherlands

Determining the Clinical Relevance of the inTeraction Between AprepitaNt aNd EtoposiDe

Completed

Conditions: Testicular Cancer

Interventions: Other: Blood sampling - Pharmacokinetic assessment

First Posted Date: 2021-06-22

Last Posted Date: 2022-09-10

Lead Sponsor: Radboud University Medical Center

Target Recruit Count: 17

Registration Number: NCT04935255

Locations: 🇳🇱
Radboud UMC, Nijmegen, Netherlands

Dose Tapering and Early Discontinuation to InCreAse cosT-effectIveness Of Immunotherapy for NSCLC

Phase 3

Recruiting

Conditions: NSCLC

Interventions: Drug: Pembrolizumab

First Posted Date: 2021-06-02

Last Posted Date: 2024-04-11

Lead Sponsor: Radboud University Medical Center

Target Recruit Count: 750

Registration Number: NCT04909684

Locations: 🇳🇱
Radboudumc, Nijmegen, Gelderland, Netherlands

CD8+ T-cell PET/CT Imaging in COVID-19 Patients

Terminated

Conditions: T-cell
Lymphopenia Due to COVID-19
PET Imaging

Interventions: Diagnostic Test: [89Zr]Df-IAB22M2C PET/CT scan

First Posted Date: 2021-05-06

Last Posted Date: 2025-04-02

Lead Sponsor: Radboud University Medical Center

Target Recruit Count: 5

Registration Number: NCT04874818

Locations: 🇳🇱
Radboud university medical center, Nijmegen, Gelderland, Netherlands

Cemiplimab for Secondary Angiosarcomas

Phase 2

Completed

Conditions: Secondary Angiosarcoma
Locally Advanced Sarcoma
Metastasis

Interventions: Drug: Cemiplimab

First Posted Date: 2021-05-05

Last Posted Date: 2024-10-31

Lead Sponsor: Radboud University Medical Center

Target Recruit Count: 18

Registration Number: NCT04873375

Locations: 🇳🇱
RadboudUMC, Nijmegen, Netherlands

Safety and Efficacy of R0.6C Vaccine

Phase 1

Completed

Conditions: Malaria
Malaria,Falciparum

Interventions: Biological: R0.6C transmission blocking vaccine

First Posted Date: 2021-04-28

Last Posted Date: 2025-03-05

Lead Sponsor: Radboud University Medical Center

Target Recruit Count: 32

Registration Number: NCT04862416

Locations: 🇳🇱
Radboud university medical center, Nijmegen, Gelderland, Netherlands

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy